search
Back to results

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

Primary Purpose

Breast Carcinoma, Lung Carcinoma

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Health Education
Health Promotion and Education
Patient Navigation
Survey Administration
Sponsored by
Jonsson Comprehensive Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Breast Carcinoma

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age: Breast screening > 40 Lung screening 50-80 Male (M) or Female (F) Current, former, or never smokers Close family or friend with smoking history (in or out of state) Exclusion Criteria: Age: Breast screening < 40 Lung screening < 50 or > 80 Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded Persons with an active cancer

Sites / Locations

  • UCLA / Jonsson Comprehensive Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Screening (electronic patient portal, patient navigation)

Arm Description

Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.

Outcomes

Primary Outcome Measures

Increased rates of lung and breast cancer screening adherence
By following up with patients over the defined study period and assessing whether they obtained an incidence screen completed at one-year +/- 3 months from the recommended time. Will also measure the rates of survey completion by consented participants, the number of clicks and time spent reviewing educational materials, and the number of new participants who contacted the program through a referral by another participant.

Secondary Outcome Measures

Success of "sphere of influence" model
Considered successful if increased lung cancer screening referrals are a direct result of women receiving screening mammograms inviting and educating friends and family about lung cancer screening.

Full Information

First Posted
July 28, 2023
Last Updated
July 28, 2023
Sponsor
Jonsson Comprehensive Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05978128
Brief Title
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
Official Title
Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 30, 2023 (Anticipated)
Primary Completion Date
September 30, 2028 (Anticipated)
Study Completion Date
September 30, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jonsson Comprehensive Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.
Detailed Description
PRIMARY OBJECTIVES: I. Determine the number of patients undergoing breast screening who are eligible to participate in lung screening. II. Determine whether patients currently participating in cancer screening (breast OR lung) are successful as "cancer screening advocates." III. Determine whether laypersons who are aware of screening (including those who accompany friends and family members to their screening appointments) are successful as "cancer screening advocates." IV. Identify knowledge base and psychological barriers to screening through surveys of potential screening participants. OUTLINE: Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study. After completion of study intervention, participants are followed up yearly for up to 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Carcinoma, Lung Carcinoma

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
800 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Screening (electronic patient portal, patient navigation)
Arm Type
Experimental
Arm Description
Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
Intervention Type
Behavioral
Intervention Name(s)
Health Education
Intervention Description
Access electronic patient portal with educational material
Intervention Type
Other
Intervention Name(s)
Health Promotion and Education
Intervention Description
Receive materials on breast/lung cancer screening
Intervention Type
Behavioral
Intervention Name(s)
Patient Navigation
Other Intervention Name(s)
Patient Navigator Program
Intervention Description
Interact with a patient navigator
Intervention Type
Other
Intervention Name(s)
Survey Administration
Intervention Description
Ancillary studies
Primary Outcome Measure Information:
Title
Increased rates of lung and breast cancer screening adherence
Description
By following up with patients over the defined study period and assessing whether they obtained an incidence screen completed at one-year +/- 3 months from the recommended time. Will also measure the rates of survey completion by consented participants, the number of clicks and time spent reviewing educational materials, and the number of new participants who contacted the program through a referral by another participant.
Time Frame
Up to 3 years
Secondary Outcome Measure Information:
Title
Success of "sphere of influence" model
Description
Considered successful if increased lung cancer screening referrals are a direct result of women receiving screening mammograms inviting and educating friends and family about lung cancer screening.
Time Frame
Up to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: Breast screening > 40 Lung screening 50-80 Male (M) or Female (F) Current, former, or never smokers Close family or friend with smoking history (in or out of state) Exclusion Criteria: Age: Breast screening < 40 Lung screening < 50 or > 80 Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded Persons with an active cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashley E Prosper
Organizational Affiliation
UCLA / Jonsson Comprehensive Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA / Jonsson Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley E. Prosper
Phone
310-825-0958
Email
APROSPER@MEDNET.UCLA.EDU
First Name & Middle Initial & Last Name & Degree
Ashley E. Prosper

12. IPD Sharing Statement

Learn more about this trial

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

We'll reach out to this number within 24 hrs